A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Clover Health Investments, Corp. CLOV
Weak broader-coverage candidate · Clover Health Investments, Corp.
On FrontierLab's discovery record since 2026-06-16 (9 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Weak" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-07-25), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | 48.7% |
|---|---|
| Gross margin | 18.4% |
| Gross profits / assets | 0.58 |
| Rule of 40 | 46.1 |
| Net margin | -2.6% |
| Cash runway (months) | — |
| PEG | — |
| Price / sales | 1 |
Quality checklist
- ✓ Revenue growth — 48.7% (pass ≥ 20%)
- ✓ Gross profits / assets — 0.58 (pass ≥ 0.33)
- ✗ Gross margin — 18.4% (pass ≥ 60%)
- ✓ Cash generation
- ✗ Share dilution — 7.1%
Fundamentals — snapshot as of 2026-07-25
| Stage | Established |
|---|---|
| Share issuance (YoY) | 7.1% · heavy issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | — |
| EPS (trailing) | $-0.11 |
| Burn multiple | — |
| Gross-margin trend (pts) | -8 |
| Cash / assets | 0.25 |
| Net debt / EBITDA | — |
| Statements as of | Q1 FY2026 · filed 2026-05-08 |
Momentum context — a snapshot from 2026-07-25, not current
| Price at surface | $4.32 (as of 2026-07-25) |
|---|---|
| 52-week range | $1.58 – $5.59 |
| % off 52-wk high | -22.7% |
| RSI (14) | 43 |
| Relative volume | 0.5× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-07-25 (end-of-day). How grades are computed →